10039-64-2

Usage

Uses

Used in Organic Synthesis:
Ethyl 3-(m-aminophenyl)propionate is used as a building block in the synthesis of various organic compounds, contributing to the formation of complex molecules and structures.
Used in Pharmaceutical Industry:
Ethyl 3-(m-aminophenyl)propionate is used as an intermediate in the production of pharmaceuticals, playing a crucial role in the development of new drugs and medications.
Used in Chemical Research:
Ethyl 3-(m-aminophenyl)propionate is used as a research compound in academic and industrial laboratories, aiding in the investigation of chemical reactions and properties.
Used in Material Science:
Ethyl 3-(m-aminophenyl)propionate is used as a component in the development of new materials, potentially contributing to advancements in areas such as polymers and coatings.

InChI:InChI=1/C11H15NO2/c1-2-14-11(13)7-6-9-4-3-5-10(12)8-9/h3-5,8H,2,6-7,12H2,1H3

Upstream product

• 5396-71-4 ethyl 3-(3-nitrophenyl)acrylate 
• 621-19-2 (E)-ethyl 3-(3-nitrophenyl)acrylate 
• 7440-44-0 pyrographite 
• 99-61-6 3-nitro-benzaldehyde 
• 64-17-5 ethanol 
• 1664-54-6 3-(3-aminophenyl)propionic acid 
• 1664-57-9 3-(3-nitrophenyl)propanoic acid 
• 7116-33-8 ethyl 3-(3-nitrophenyl)propanoate 
• 555-68-0 m-Nitrocinnamic Acid 

Downstream Products

• 10036-20-1 3-(3-cyanophenyl)propanoic acid ethyl ester 
• 121269-65-6 ethyl 3-(3-iodophenyl)propanoate 
• 99255-43-3 ethyl 3-(3-aminophenyl)propanoate hydrochloride 
• 383669-42-9 ethyl 3-[3-[[(3S,5R)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]aminophenyl]propionate 
• 897373-51-2 3-(3-hydrazino-phenyl)-propionic acid ethyl ester 
• 1308256-05-4 ethyl 3-(2-(chlorosulfonyl)-5-(2,2,2-trifluoroacetamido)phenyl)propanoate 
• 1308254-79-6 ethyl 3-(2-(N-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)sulfamoyl)-5-(2,2,2-trifluoroacetamido)phenyl)propanoate 
• 1308255-01-7 methyl 3-(5-amino-2-(N-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)sulfamoyl)phenyl)propanoate 
• 1308255-02-8 ethyl 3-(5-amino-2-(N-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)sulfamoyl)phenyl)propanoate 
• 1308256-04-3 ethyl 3-(3-(2,2,2-trifluoroacetamido)phenyl)propanoate 
• 1261078-81-2 3-(3-(quinoxalin-3-ylamino)phenyl)propanoic acid 
• 1261078-78-7 3-(3-(6-nitroquinoxalin-3-ylamino)phenyl)propanoic acid 
• 1310877-60-1 ethyl 3-(3-(6-nitroquinoxalin-3-ylamino)phenyl)propanoate 
• 1384262-65-0 ethyl 3-(3-(dihexylamino)phenyl)propanoate 

Relevant academic research and scientific papers

Short synthesis of ethyl 3-(3-aminophenyl)propanoate

A short and effective synthesis of ethyl 3-(3-aminophenyl)propanoate is presented, employing a tandem Knoevenagel condensation/alkylidene reduction of 3-nitrobenzaldehyde with Meldrum's acid in TEAF (triethylammonium formate) followed by reduction of the

Development of second-generation small-molecule RhoA inhibitors with enhanced water solubility, tissue potency, and significant in vivo efficacy

RhoA, a member of the Rho GTPases, is involved in a variety of cellular functions and could be a suitable therapeutic target for the treatment of cardiovascular diseases. However, few small-molecule RhoA inhibitors have been reported. Based on our previously reported lead compounds, 32 new 2-substituted quinoline (or quinoxaline) derivatives were synthesized and tested in biological assays. Six compounds showed high RhoA inhibitory activities, with IC50 values of 1.17-1.84 μM. Among these, (E)-3-(3-(ethyl(quinolin-2-yl)amino)phenyl)acrylic acid (26b) and (E)-3-(3-(butyl(quinolin-2-yl)amino)phenyl)acrylic acid (26d) demonstrated noticeable vasorelaxation effects against phenylephrine-induced contraction in thoracic aorta artery rings, and compound 26b had good water solubility and showed significant in vivo efficacy, which was similar to that of 5-(1,4-diazepane-1-sulfonyl)isoquinoline (fasudil) in a subarachnoid hemorrhage-cardiovascular model. To the best of our knowledge, compound 26b is the first example of a small-molecule RhoA inhibitor with potent in vivo efficacy, which could serve as a good lead for designing cardiovascular agents.

Molecular design to improve the performance of donor-π acceptor near-IR organic dye-sensitized solar cells

Near-dye experience: Long, flexible carbon chains in the lateral anchoring groups of the donor part of a donor-π acceptor organic dye increase the power conversion efficiency dramatically. This performance enhancement can be ascribed to the prevention of the formation of molecular aggregates on the semiconductor nanoparticles, resulting in a lower recombination rate between transported electrons and I3- ions. A cell based on the new dye, HY113, gives a maximum IPCE value of 93% at 660nm. Copyright

Improving the Potency of Cancer Immunotherapy by Dual Targeting of IDO1 and DNA

Herein we report the first exploration of a dual-targeting drug design strategy to improve the efficacy of small-molecule cancer immunotherapy. New hybrids of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors and DNA alkylating nitrogen mustards that respectively target IDO1 and DNA were rationally designed. As the first-in-class examples of such molecules, they were found to exhibit significantly enhanced anticancer activity in vitro and in vivo with low toxicity. This proof-of-concept study has established a critical step toward the development of a novel and effective immunotherapy for the treatment of cancers.

N, N-disubstituted benzo-nitrogen heterocycles-2-amine compound and use thereof

The invention mainly relates to an N,N-double substituted benzoazacyclo-2-amide compound and an application thereof. The N,N-double substituted benzoazacyclo-2-amide compound is a compound shown as formula I or a salt formed by a medical acid or alkali. The compound provided by the invention has strong inhibition activity on RhoA protease which is tightly related with cardiovascular and cerebrovascular diseases. The compound provided by the invention is hopeful to be developed into a RhoA protease small-molecule inhibitor type cardiovascular and cerebrovascular disease treatment medicine.

PROTEASOME ACTIVITY ENHANCING COMPOUNDS

The present invention is directed to compounds having the Formula (I), (II), (III), (IV), and (V), compositions thereof, the methods of synthesis of the compouds of interest, and to methods for the treatment of a condition associated with a dysfunction in proteostasis, such as cancer, inflammatory conditions, neurodegeneration, metabolic conditions, comprising administering an effective amount of a compound of the invention.

The role of a dipeptide outer-coordination sphere on H2- production catalysts: Influence on catalytic rates and electron transfer

The outer-coordination sphere of enzymes acts to fine-tune the active site reactivity and control catalytic rates, suggesting that incorporation of analogous structural elements into molecular catalysts may be necessary to achieve rates comparable to thos

BORON-CONTAINING SMALL MOLECULES

This invention relates to 6-substituted benzoxaborole compounds of the following formula and their use for treating bacterial infections.

Design and synthesis of small molecule RhoA inhibitors: A new promising therapy for cardiovascular diseases?

RhoA is a member of Rho GTPases, a subgroup of the Ras superfamily of small GTP-binding proteins. RhoA, as an important regulator of diverse cellular signaling pathways, plays significant roles in cytoskeletal organization, transcription, and cell-cycle progression. The RhoA/ROCK inhibitors have emerged as a new promising treatment for cardiovascular diseases. However, to date, RhoA inhibitors are macromolecules, and to our knowledge, small molecular-based inhibitors have not been reported. In this study, a series of first-in-class small molecular RhoA inhibitors have been discovered by using structure-based virtual screening in conjunction with chemical synthesis and bioassay. Virtual screening of ～200,000 compounds, followed by SPR-based binding affinity assays resulted in three compounds with binding affinities to RhoA at the micromolar level (compounds 1-3). Compound 1 was selected for further structure modifications in considering binding activity and synthesis ease. Fourty-one new compounds (1, 12a-v, 13a-h, and 14a-j) were designed and synthesized accordingly. It was found that eight (12a, 12j, 14a, 14b, 14d, 14e, 14 g, and 14h) showed high RhoA inhibition activities with IC50 values of 1.24 to 3.00 μM. A pharmacological assay indicated that two compounds (14g and 14 h) demonstrated noticeable vasorelaxation effects against PE-induced contraction in thoracic aorta artery rings and served as good leads for developing more potent cardiovascular agents.

ENZYME MODULATORS AND TREATMENTS

Novel compounds and methods of using those compounds for the treatment of inflammatory conditions, hyperproliferative diseases, cancer, and diseases characterized by hypervascularization are provided. In a preferred embodiment, modulation of the activation state of p38 kinase protein ab1 kinase protein, bcr-ab1 kinase protein, braf kinase protein, VEGFR kinase protein, or PDGFR kinase protein comprises the step of contacting said kinase protein with the novel compounds.